||Thursday,7 April 2016, 18:00～
|| Seminar-shitsu 1, IDAC Research building 7F
|| Lung Transplantation in cGVHD after Allogeneic Hematopoietic Stem Cell Transplantation
||Hyo Chae Paik, M.D., Ph.D.
||Professor and Chairman, Department of Thoracic and Cardiovascular
Surgery, Yonsei University College of Medicine, Seoul, Korea
|| Yasushi Matsuda（Department of Thoracic Surgery・ext.8526）
|| Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. However, pulmonary complications are a major cause of morbidity and mortality in these patients, and bronchiolitis obliterans syndrome (BOS) remains the most challenging chronic pulmonary complications. For selected patients with BOS, lung transplantation (LTx) has been a treatment option. From Jan. 2010 to Dec. 2015, a total of 124 LTx were performed in our institution among which 13 cases were due to BOS following allogeneic HSCT. There were 8 males and 5 females, with age ranged from 16 to 56 years (mean 29.4 years). The underlying hematologic diseases were 11 leukemia and 2 aplastic anemia. Ten patients used peripheral blood and 3 used bone marrow as a source of stem cell. The mean time from HSCT to BOS ranged from 7 months to 79.8 months (mean 20.3 months), and the mean time from the diagnosis of BOS to LTx ranged from 7 months to 59.8 months (mean 29.2 months). There were 4 short term mortality and the remaining 9 patients are in excellent condition with normal daily activity. LTx is a reasonable approach for highly selected patients with severe chronic lung disease following HSCT, and further studies with multi-center are necessary to determine optimal management plan for these patients.